Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?
作者信息
Teitelbaum Steven L, Seton Margaret P, Saag Kenneth G
机构信息
Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, Missouri 63110, USA.
出版信息
Arthritis Rheum. 2011 Feb;63(2):325-8. doi: 10.1002/art.30135.
Abstract
摘要
相似文献
1
Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?双膦酸盐类药物是否应用于糖皮质激素诱导的骨质疏松症的长期治疗？
Arthritis Rheum. 2011 Feb;63(2):325-8. doi: 10.1002/art.30135.
2
Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.地舒单抗对合并风湿性疾病的糖皮质激素诱导的骨质疏松症患者有效，无论其是否使用过抗骨质疏松药物。
J Bone Miner Metab. 2019 May;37(3):554-562. doi: 10.1007/s00774-018-0955-7. Epub 2018 Sep 5.
3
Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.双膦酸盐类药物预防马来西亚糖皮质激素性骨质疏松症相关骨折的成本效益分析
Int J Rheum Dis. 2018 Mar;21(3):647-655. doi: 10.1111/1756-185X.13206. Epub 2017 Nov 3.
4
Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.日本系统性风湿病患者中，从每周使用双膦酸盐转换为每月使用米诺膦酸盐治疗和预防糖皮质激素性骨质疏松症的患者满意度和疗效：一项随机临床试验。
Arch Osteoporos. 2018 Jun 13;13(1):67. doi: 10.1007/s11657-018-0451-7.
5
Glucocorticoid-induced osteoporosis and osteonecrosis.糖皮质激素诱导的骨质疏松症和骨坏死。
Endocrinol Metab Clin North Am. 2012 Sep;41(3):595-611. doi: 10.1016/j.ecl.2012.04.004. Epub 2012 May 23.
6
Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.长期接受糖皮质激素治疗的风湿病患者骨质疏松性骨折的患病率和发病率：糖皮质激素诱导骨质疏松工具（GIOTTO）研究
Reumatismo. 2017 May 22;69(1):30-39. doi: 10.4081/reumatismo.2017.922.
7
Advances in treatment of glucocorticoid-induced osteoporosis.糖皮质激素性骨质疏松症的治疗进展
Curr Opin Endocrinol Diabetes Obes. 2017 Dec;24(6):411-417. doi: 10.1097/MED.0000000000000368.
8
9
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.2017 年美国风湿病学会糖皮质激素诱导性骨质疏松症预防和治疗指南。
Arthritis Rheumatol. 2017 Aug;69(8):1521-1537. doi: 10.1002/art.40137. Epub 2017 Jun 6.
10
Glucocorticoid-induced Osteoporosis.糖皮质激素性骨质疏松症
Rheum Dis Clin North Am. 2016 Feb;42(1):177-89, x. doi: 10.1016/j.rdc.2015.08.005. Epub 2015 Oct 24.
引用本文的文献
1
Prolonged Impact of Bisphosphonates and Glucocorticoids on Bone Mechanical Properties.双膦酸盐和糖皮质激素对骨力学性能的长期影响。
Pharmaceuticals (Basel). 2025 Jan 26;18(2):164. doi: 10.3390/ph18020164.
2
Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis.乌克兰糖皮质激素诱导性骨质疏松症防治指南。
Arch Osteoporos. 2025 Feb 24;20(1):31. doi: 10.1007/s11657-025-01512-9.
3
GLUCOCORTICOIDS IN CHRONIC DISEASE: THE GOOD, THE BAD, THE BONE.慢性疾病中的糖皮质激素：有好有坏，还有骨骼。
Trans Am Clin Climatol Assoc. 2023;133:69-80.
4
Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy.合成代谢药物在糖皮质激素诱导性骨质疏松症管理中的应用：基于证据的长期安全性、疗效及治疗地位综述
Core Evid. 2019 Aug 23;14:41-50. doi: 10.2147/CE.S172820. eCollection 2019.
5
Tetracycline Analogs Inhibit Osteoclast Differentiation by Suppressing MMP-9-Mediated Histone H3 Cleavage.四环素类似物通过抑制 MMP-9 介导的组蛋白 H3 裂解抑制破骨细胞分化。
Int J Mol Sci. 2019 Aug 19;20(16):4038. doi: 10.3390/ijms20164038.
6
Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.糖皮质激素性骨质疏松症的治疗现状与新进展。
Drugs. 2019 Jul;79(10):1065-1087. doi: 10.1007/s40265-019-01145-6.
7
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats.二甲双胍对大鼠糖皮质激素性骨质疏松的预防作用。
J Bone Miner Metab. 2019 Sep;37(5):805-814. doi: 10.1007/s00774-019-00989-y. Epub 2019 Jan 31.
8
Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.接受双膦酸盐治疗的绝经后韩国女性发生非典型股骨骨折的相关易感因素：单中心 8 年经验。
Osteoporos Int. 2017 Nov;28(11):3251-3259. doi: 10.1007/s00198-017-4169-y. Epub 2017 Jul 27.
9
High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.高尖型股骨局部反应在长期接受糖皮质激素和双膦酸盐治疗的自身免疫性疾病患者中常发展为完全和不完全非典型股骨骨折。
Osteoporos Int. 2017 Aug;28(8):2367-2376. doi: 10.1007/s00198-017-4038-8. Epub 2017 Apr 13.
10
One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy.糖皮质激素对骨密度的一年影响：高剂量和低剂量治疗队列的荟萃分析。
RMD Open. 2016 Sep 12;2(2):e000313. doi: 10.1136/rmdopen-2016-000313. eCollection 2016.
本文引用的文献
1
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.非典型转子下和骨干股骨骨折：美国骨矿研究学会工作组报告。
J Bone Miner Res. 2010 Nov;25(11):2267-94. doi: 10.1002/jbmr.253.
2
Calpain-6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation.钙蛋白酶-6，一种糖皮质激素的靶分子，通过细胞骨架组织和微管乙酰化来调节破骨细胞的骨吸收。
J Bone Miner Res. 2011 Mar;26(3):657-65. doi: 10.1002/jbmr.241.
3
Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.接受特立帕肽或阿仑膦酸钠治疗的糖皮质激素性骨质疏松症患者的骨形成标志物。
Bone. 2010 Apr;46(4):929-34. doi: 10.1016/j.bone.2009.12.021. Epub 2010 Jan 6.
4
Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.在糖皮质激素诱导的骨质疏松症患者中，特立帕肽或阿仑膦酸钠治疗的基础糖皮质激素剂量和骨密度反应。
J Rheumatol. 2010 Jan;37(1):141-8. doi: 10.3899/jrheum.090411. Epub 2009 Nov 16.
5
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.特立帕肽与阿仑膦酸钠治疗糖皮质激素性骨质疏松症的效果：一项随机、双盲、对照试验的36个月结果
Arthritis Rheum. 2009 Nov;60(11):3346-55. doi: 10.1002/art.24879.
6
Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.地舒单抗对同时接受糖皮质激素或双膦酸盐治疗的类风湿关节炎患者骨密度和骨转换的影响。
Ann Rheum Dis. 2010 May;69(5):872-5. doi: 10.1136/ard.2009.112920. Epub 2009 Sep 3.
7
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.地舒单抗对绝经后妇女由阿伦膦酸盐治疗转换时的骨密度和骨转换的影响。
J Bone Miner Res. 2010 Jan;25(1):72-81. doi: 10.1359/jbmr.090716.
8
Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.接受双膦酸盐治疗的低能量皮质骨骨折患者骨活检中的骨转换：病例系列
Calcif Tissue Int. 2009 Jul;85(1):37-44. doi: 10.1007/s00223-009-9263-5. Epub 2009 Jun 23.
9
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.静脉注射双膦酸盐相关颌骨坏死：骨闪烁显像作为早期指标
J Oral Maxillofac Surg. 2009 Jul;67(7):1363-72. doi: 10.1016/j.joms.2009.03.005.
10
Bisphosphonates: mechanism of action and role in clinical practice.双膦酸盐类药物：作用机制及在临床实践中的作用
Mayo Clin Proc. 2008 Sep;83(9):1032-45. doi: 10.4065/83.9.1032.
Zotero 插件